Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment
出版年份 2019 全文链接
标题
Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment
作者
关键词
-
出版物
BIODRUGS
Volume 33, Issue 4, Pages 411-422
出版商
Springer Science and Business Media LLC
发表日期
2019-06-12
DOI
10.1007/s40259-019-00362-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The evolution of biosimilars in oncology, with a focus on trastuzumab
- (2018) N.A. Nixon et al. Current Oncology
- Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
- (2017) Seokkyun Kim et al. mAbs
- A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects
- (2016) Xavier Pivot et al. CLINICAL THERAPEUTICS
- N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins
- (2016) Fabian Higel et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
- (2016) A Musolino et al. PHARMACOGENOMICS JOURNAL
- Targeting FcRn for the modulation of antibody dynamics
- (2015) E. Sally Ward et al. MOLECULAR IMMUNOLOGY
- Biosimilars lining up to compete with Herceptin – opportunity knocks
- (2014) Kevin M Nelson et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines
- (2011) D. M. Collins et al. ANNALS OF ONCOLOGY
- Acceptable changes in quality attributes of glycosylated biopharmaceuticals
- (2011) Martin Schiestl et al. NATURE BIOTECHNOLOGY
- Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
- (2010) K. Tamura et al. ANNALS OF ONCOLOGY
- HER-2 Signaling and Inhibition in Breast Cancer
- (2009) B. Browne et al. CURRENT CANCER DRUG TARGETS
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
- (2008) Alessandra Beano et al. Journal of Translational Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now